Pub Date : 2026-11-09DOI: 10.1038/s41582-026-01283-y
Micol Avenali, Alberto Imarisio, Enza Maria Valente
Parkinson disease (PD) is a heterogeneous neurodegenerative disorder characterized by variable progression and treatment response. Over the past three decades, genetic discoveries have reshaped our understanding of PD biology, identifying rare monogenic forms, strong genetic risk variants and a large set of common and rare genetic variants variably contributing to PD heritability. These findings led to the identification of key pathways implicated in the neurodegenerative process, including protein misprocessing, lysosomal and mitochondrial impairment, and altered immune response. In this Review, we describe the evolution of PD genetics and discuss its current clinical impact and future role in shaping precision medicine, from diagnosis and prognosis to the development of disease-modifying therapies. Genetic information is increasingly used to support clinical decision-making, improve patient counselling and identify biologically distinct forms of PD. Importantly, genetic insights are driving therapeutic innovation, enabling targeted strategies and genetically stratified clinical trials. Despite ongoing challenges such as incomplete penetrance, variable expression of disease and missing heritability across multiple ancestries, integrating genetic knowledge into research and clinical practice is accelerating the transition towards precision medicine in PD, providing a framework for more personalized care and improved patient outcomes.
{"title":"Translating Parkinson disease genetics into clinical benefit.","authors":"Micol Avenali, Alberto Imarisio, Enza Maria Valente","doi":"10.1038/s41582-026-01283-y","DOIUrl":"https://doi.org/10.1038/s41582-026-01283-y","url":null,"abstract":"<p><p>Parkinson disease (PD) is a heterogeneous neurodegenerative disorder characterized by variable progression and treatment response. Over the past three decades, genetic discoveries have reshaped our understanding of PD biology, identifying rare monogenic forms, strong genetic risk variants and a large set of common and rare genetic variants variably contributing to PD heritability. These findings led to the identification of key pathways implicated in the neurodegenerative process, including protein misprocessing, lysosomal and mitochondrial impairment, and altered immune response. In this Review, we describe the evolution of PD genetics and discuss its current clinical impact and future role in shaping precision medicine, from diagnosis and prognosis to the development of disease-modifying therapies. Genetic information is increasingly used to support clinical decision-making, improve patient counselling and identify biologically distinct forms of PD. Importantly, genetic insights are driving therapeutic innovation, enabling targeted strategies and genetically stratified clinical trials. Despite ongoing challenges such as incomplete penetrance, variable expression of disease and missing heritability across multiple ancestries, integrating genetic knowledge into research and clinical practice is accelerating the transition towards precision medicine in PD, providing a framework for more personalized care and improved patient outcomes.</p>","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":" ","pages":""},"PeriodicalIF":31.2,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149379823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-11-09DOI: 10.1038/s41582-026-01289-6
Maria Bonaria Uccheddu
{"title":"Hormonal changes must be part of the conversation in neurological care.","authors":"Maria Bonaria Uccheddu","doi":"10.1038/s41582-026-01289-6","DOIUrl":"https://doi.org/10.1038/s41582-026-01289-6","url":null,"abstract":"","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":" ","pages":""},"PeriodicalIF":31.2,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149379820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-11-06DOI: 10.1038/s41582-026-01292-x
Heather Wood
{"title":"CAR T cells show early promise in progressive multiple sclerosis.","authors":"Heather Wood","doi":"10.1038/s41582-026-01292-x","DOIUrl":"https://doi.org/10.1038/s41582-026-01292-x","url":null,"abstract":"","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":" ","pages":""},"PeriodicalIF":31.2,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149371304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-10-26DOI: 10.1038/s41582-026-01272-1
Jennifer L Gommerman, Katerina Akassoglou, Sergio E Baranzini, Burkhard Becher, Fabienne Brilot, Gonçalo Castelo-Branco, Shannon E Dunn, Maryam Faiz, Alexander Flügel, Nader Ghasemlou, Erin M Gibson, Judith M Greer, Denis Gris, Cole A Harrington, Steffen Jung, Lorraine V Kalia, Thomas Korn, Gurumoorthy Krishnamoorthy, Roland S Liblau, Francesca Odoardi, Laura Piccio, Anne-Katrin Pröbstel, Francisco J Quintana, Valeria Ramaglia, Manu Rangachari, Olga L Rojas, Marc J Ruitenberg, Scott Russo, Dorothy P Schafer, Benjamin M Segal, Jana Vukovic, Chao Wang, Michael A Wheeler, Heinz Wiendl, V Wee Yong, Frauke Zipp, Veronique E Miron
Neuroimmunology is a rapidly expanding field in which many breakthroughs have been fuelled by studies in animal models that capture aspects of human neurological disease. However, the variety of animal models available, with their relative merits and drawbacks, is not well documented in the literature, posing a hurdle for scientists who are venturing into the world of neuroimmunology. Moreover, nuances between animal models, their utility for studying neuroimmunological processes and the variables that affect their associated clinical and pathological outcomes can affect the reproducibility and clinical relevance of findings at the preclinical stage. In this Review, the International Society of Neuroimmunology White Paper Task Force describes animal models that can be used to study neuroimmunological aspects of neurological disease and the intrinsic and extrinsic factors that affect readouts from these models. We provide guidance on how to manipulate these factors to gain insight into neuroimmunology and to control them for improved reproducibility. We also consider the advantages and limitations of available tools, including robust genetic systems, neuroimmunological imaging, functional readouts and omics-based cell profiling. Finally, we discuss how animal models have advanced drug development to treat neuroimmunological diseases and how the same principles can provide insight into a variety of neurological disorders. We aim to provide guidance on how to optimize the use of animal models to gain insight into neuroimmunological mechanisms and support the preclinical drug discovery pipeline.
{"title":"Use of animal models to understand CNS neuroimmunology - guidance from the International Society for Neuroimmunology White Paper Task Force.","authors":"Jennifer L Gommerman, Katerina Akassoglou, Sergio E Baranzini, Burkhard Becher, Fabienne Brilot, Gonçalo Castelo-Branco, Shannon E Dunn, Maryam Faiz, Alexander Flügel, Nader Ghasemlou, Erin M Gibson, Judith M Greer, Denis Gris, Cole A Harrington, Steffen Jung, Lorraine V Kalia, Thomas Korn, Gurumoorthy Krishnamoorthy, Roland S Liblau, Francesca Odoardi, Laura Piccio, Anne-Katrin Pröbstel, Francisco J Quintana, Valeria Ramaglia, Manu Rangachari, Olga L Rojas, Marc J Ruitenberg, Scott Russo, Dorothy P Schafer, Benjamin M Segal, Jana Vukovic, Chao Wang, Michael A Wheeler, Heinz Wiendl, V Wee Yong, Frauke Zipp, Veronique E Miron","doi":"10.1038/s41582-026-01272-1","DOIUrl":"10.1038/s41582-026-01272-1","url":null,"abstract":"<p><p>Neuroimmunology is a rapidly expanding field in which many breakthroughs have been fuelled by studies in animal models that capture aspects of human neurological disease. However, the variety of animal models available, with their relative merits and drawbacks, is not well documented in the literature, posing a hurdle for scientists who are venturing into the world of neuroimmunology. Moreover, nuances between animal models, their utility for studying neuroimmunological processes and the variables that affect their associated clinical and pathological outcomes can affect the reproducibility and clinical relevance of findings at the preclinical stage. In this Review, the International Society of Neuroimmunology White Paper Task Force describes animal models that can be used to study neuroimmunological aspects of neurological disease and the intrinsic and extrinsic factors that affect readouts from these models. We provide guidance on how to manipulate these factors to gain insight into neuroimmunology and to control them for improved reproducibility. We also consider the advantages and limitations of available tools, including robust genetic systems, neuroimmunological imaging, functional readouts and omics-based cell profiling. Finally, we discuss how animal models have advanced drug development to treat neuroimmunological diseases and how the same principles can provide insight into a variety of neurological disorders. We aim to provide guidance on how to optimize the use of animal models to gain insight into neuroimmunological mechanisms and support the preclinical drug discovery pipeline.</p>","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":" ","pages":""},"PeriodicalIF":31.2,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149271285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-10-23DOI: 10.1038/s41582-026-01274-z
Elena Rossini, Matteo Garibaldi, Michael G Hanna, Robert D S Pitceathly, Chiara Pizzamiglio
Mitochondrial dysfunction is increasingly recognized as a shared downstream pathogenic mechanism across a wide spectrum of neurological disorders, ranging from primary mitochondrial diseases to conditions including amyotrophic lateral sclerosis, Alzheimer disease, Parkinson disease, multiple sclerosis, hereditary ataxias and idiopathic inflammatory myopathies. This Review examines the role of mitochondrial biomarkers in improving diagnostic accuracy, patient stratification and monitoring of disease progression and therapeutic response. Primary mitochondrial diseases are presented as proof-of-concept models of impaired oxidative phosphorylation, providing a framework for biomarker identification and validation with translational relevance to other neurological diseases. Mitochondrial biomarkers can be broadly categorized into four domains: fluid biomarkers, reflecting metabolic alterations and stress signalling; genetic biomarkers, capturing mitochondrial DNA integrity and dynamics; multi-omics approaches, integrating transcriptomic, proteomic and metabolomic signatures; and imaging biomarkers, enabling in vivo assessment of structural and functional consequences of mitochondrial dysfunction. Across disorders, these biomarkers reveal shared disturbances in bioenergetics, redox homeostasis, mitochondrial genome maintenance and inflammatory signalling. However, clinical implementation remains limited by methodological heterogeneity, biological variability and reduced disease specificity. Integrated, multimodal biomarker strategies, combined with longitudinal validation, will be essential for supporting precision medicine and guiding the development of therapies to target mitochondrial pathways in neurology.
{"title":"Mitochondrial dysfunction in neurology: biomarkers and clinical implications.","authors":"Elena Rossini, Matteo Garibaldi, Michael G Hanna, Robert D S Pitceathly, Chiara Pizzamiglio","doi":"10.1038/s41582-026-01274-z","DOIUrl":"https://doi.org/10.1038/s41582-026-01274-z","url":null,"abstract":"<p><p>Mitochondrial dysfunction is increasingly recognized as a shared downstream pathogenic mechanism across a wide spectrum of neurological disorders, ranging from primary mitochondrial diseases to conditions including amyotrophic lateral sclerosis, Alzheimer disease, Parkinson disease, multiple sclerosis, hereditary ataxias and idiopathic inflammatory myopathies. This Review examines the role of mitochondrial biomarkers in improving diagnostic accuracy, patient stratification and monitoring of disease progression and therapeutic response. Primary mitochondrial diseases are presented as proof-of-concept models of impaired oxidative phosphorylation, providing a framework for biomarker identification and validation with translational relevance to other neurological diseases. Mitochondrial biomarkers can be broadly categorized into four domains: fluid biomarkers, reflecting metabolic alterations and stress signalling; genetic biomarkers, capturing mitochondrial DNA integrity and dynamics; multi-omics approaches, integrating transcriptomic, proteomic and metabolomic signatures; and imaging biomarkers, enabling in vivo assessment of structural and functional consequences of mitochondrial dysfunction. Across disorders, these biomarkers reveal shared disturbances in bioenergetics, redox homeostasis, mitochondrial genome maintenance and inflammatory signalling. However, clinical implementation remains limited by methodological heterogeneity, biological variability and reduced disease specificity. Integrated, multimodal biomarker strategies, combined with longitudinal validation, will be essential for supporting precision medicine and guiding the development of therapies to target mitochondrial pathways in neurology.</p>","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":" ","pages":""},"PeriodicalIF":31.2,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149245702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-10-19DOI: 10.1038/s41582-026-01276-x
Zirui Fan, Bingxin Zhao
Population-based cohorts that combine genetic data with whole-body multimodal imaging are transforming how we map the genetic architecture of the brain in its broader bodily context. Historically, imaging genetics has focused largely on single organs, especially the brain, with separate efforts targeting the heart, skeleton and other organs for systemic diseases, and limited integration across organ systems. Yet, strong brain-body interactions and the high multimorbidity of brain and systemic diseases highlight the need for a brain-centred multi-organ perspective. Here we introduce the emerging field of brain-focused multi-organ imaging genetics, outlining key data resources and interdisciplinary analytical frameworks for large-scale multi-organ genetic discovery and reviewing the genetic associations between brain diseases and imaging phenotypes across organ systems. We discuss how these advances support a whole-body integrated view of brain health and disease and how they are beginning to reshape clinical translation for neurological conditions. We outline a roadmap for agentic artificial intelligence co-scientists that work alongside human researchers throughout the scientific discovery process, arguing that such systems will be essential for achieving an integrated understanding of brain health and disease, both as tools for individual researchers and as a collaborative infrastructure for the whole field.
{"title":"Multi-organ imaging genetics: towards an integrated view of brain, body and brain diseases.","authors":"Zirui Fan, Bingxin Zhao","doi":"10.1038/s41582-026-01276-x","DOIUrl":"https://doi.org/10.1038/s41582-026-01276-x","url":null,"abstract":"<p><p>Population-based cohorts that combine genetic data with whole-body multimodal imaging are transforming how we map the genetic architecture of the brain in its broader bodily context. Historically, imaging genetics has focused largely on single organs, especially the brain, with separate efforts targeting the heart, skeleton and other organs for systemic diseases, and limited integration across organ systems. Yet, strong brain-body interactions and the high multimorbidity of brain and systemic diseases highlight the need for a brain-centred multi-organ perspective. Here we introduce the emerging field of brain-focused multi-organ imaging genetics, outlining key data resources and interdisciplinary analytical frameworks for large-scale multi-organ genetic discovery and reviewing the genetic associations between brain diseases and imaging phenotypes across organ systems. We discuss how these advances support a whole-body integrated view of brain health and disease and how they are beginning to reshape clinical translation for neurological conditions. We outline a roadmap for agentic artificial intelligence co-scientists that work alongside human researchers throughout the scientific discovery process, arguing that such systems will be essential for achieving an integrated understanding of brain health and disease, both as tools for individual researchers and as a collaborative infrastructure for the whole field.</p>","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":" ","pages":""},"PeriodicalIF":31.2,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149224704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-10-09DOI: 10.1038/s41582-026-01278-9
Lisa Kiani
Proteomic changes associated with menopause track with cognitive ageing and dementia risk, according to new research.
根据一项新的研究,与更年期相关的蛋白质组学变化与认知衰老和痴呆风险有关。
{"title":"Menopause-associated proteomic changes link to brain ageing and dementia risk","authors":"Lisa Kiani","doi":"10.1038/s41582-026-01278-9","DOIUrl":"10.1038/s41582-026-01278-9","url":null,"abstract":"Proteomic changes associated with menopause track with cognitive ageing and dementia risk, according to new research.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"22 11","pages":"664-664"},"PeriodicalIF":31.2,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149148379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}